e-learning
resources
Madrid 2019
Sunday, 29.09.2019
Comorbidities of idiopathic pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival
E. Bárczi (Budapest, Hungary), T. Nagy (Budapest, Hungary), K. Vincze (Budapest, Hungary), N. Eszes (Budapest, Hungary), A. Bohács (Budapest, Hungary), V. Müller (Budapest, Hungary)
Source:
International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Session:
Comorbidities of idiopathic pulmonary fibrosis
Session type:
Thematic Poster
Number:
1308
Disease area:
Interstitial lung diseases, Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Bárczi (Budapest, Hungary), T. Nagy (Budapest, Hungary), K. Vincze (Budapest, Hungary), N. Eszes (Budapest, Hungary), A. Bohács (Budapest, Hungary), V. Müller (Budapest, Hungary). Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival. 1308
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Pivotal role of the HMGB1/sRAGE axis in drug-induced lung injury in advanced lung cancer with pre-existing interstitial lung disease
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
Coexistence of chronic obstructive pulmonary disease in patients with advanced non-small cell lung cancer and impact on survival
Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up
Year: 2017
Does the lung function affect the survival time in patients with resected non-small cell lung cancer?
Source: Annual Congress 2007 - Lung function parameters before and after thoracic surgery
Year: 2007
Prevalence and characterization of interstitial lung disease in a lung cancer screening program
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
A study on chemotherapy induced interstitial lung disease in patients with unresectable non-small cell lung cancer complicated by combined pulmonary fibrosis and emphysema
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Immunology-based therapeutic strategies in lung cancer and mesothelioma
Source: International Congress 2014 – Beyond tyrosine kinase inhibition: promising new developments in molecular oncology
Year: 2014
The burden of emphysema on lung cancer prognosis
Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity
Year: 2020
Surfactant protein-D level as a predictor of prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Common therapeutic approaches in IPF and lung cancer
Source: Research Seminar 2015
Year: 2015
A modified ILD-GAP index for patients with non-small cell lung cancer and interstitial lung disease
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
The Asian experience in co-existing lung cancer and interstitial lung disease
Source: International Congress 2018 – Imminent global problems in lung cancer require joint action: time for an international alliance!
Year: 2018
Lung disease induced by newer therapies for lung cancer: an update
Source: Annual Congress 2006 - Drug-induced lung injury – new aspects
Year: 2006
Impact of COPD on prognosis of lung cancer: the prespective of immunotherapy treatment
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021
Clinicopathologic features of patients with non-small cell lung cancer and chronic obstructive pulmonary disease undergoing lung cancer surgery
Source: Virtual Congress 2020 – Localised non-small cell lung cancer
Year: 2020
Chronic obstructive pulmonary disease and interstitial lung disease could predict poor long-term survivals after pulmonary resection for lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 38s
Year: 2002
A case series study on re-treatment to lung cancer after drug-induced interstitial lung disease
Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside
Year: 2018
Markers of angiogenesis in serum are correlating with disease progress in lung cancer
Source: Annual Congress 2006 - Prognostic factors in lung cancer
Year: 2006
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Source: Eur Respir J, 50 (2) 1700050; 10.1183/13993003.00050-2017
Year: 2017
Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
Source: Eur Respir J, 52 (6) 1801100; 10.1183/13993003.01100-2018
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept